# Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

> **NCT06546969** · PHASE1 · RECRUITING · sponsor: **University of Maryland, Baltimore** · enrollment: 15 (estimated)

## Conditions studied

- Biliary Tract Cancer
- Cholangiocarcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Durvalumab
- **RADIATION:** Spatially Fractionated RT
- **DEVICE:** Deep Hyperthermia

## Key facts

- **NCT ID:** NCT06546969
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-29
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06546969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06546969, "Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06546969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*